Clinical stage biotechnology company MiNK Therapeutics wrapped its initial public offering, selling 3.333 million shares at $12 each, the low end of its $12 to $14 range.
Shares of INKT will commence trading on the Nasdaq later today, but the stock is available for limit orders on Robinhood and other platforms.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.68 |
|---|---|
| 52-week range | $0.57 - $1.90 |
| 50-day moving average | $0.73 |
| 200-day moving average | $0.88 |
| Wall St. target price | $6.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.37 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.6901 from 2024-11-21
| 1 week (2024-11-15) | -8.47% |
|---|---|
| 1 month (2024-10-24) | -4.67% |
| 3 months (2024-08-23) | -15.84% |
| 6 months (2024-05-23) | -29.94% |
| 1 year (2023-11-22) | -34.28% |
|---|---|
| 2 years (2022-11-23) | -72.87% |
| 3 years (2021-11-23) | 16.92 |
| 5 years (2019-11-20) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -97.25% |
| Return on equity TTM | -1238.98% |
| Profit margin | 0% |
| Book value | $-0.52 |
| Market Capitalization | $27.3 million |
TTM: trailing 12 months
We're not expecting MiNK Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, MiNK Therapeutics's shares have ranged in value from as little as $0.57 up to $1.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MiNK Therapeutics's is 0.048. This would suggest that MiNK Therapeutics's shares are less volatile than average (for this exchange).
To put MiNK Therapeutics's beta into context you can compare it against those of similar companies.
MiNK Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.